L26/O-303 Options for fertility preservation in persons assigned male at birth
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Schneider und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Transgender and gender diverse (TGD) people seek gender-affirming care at any age to manage gender identities or expressions that differ from the gender socially attributed to their sex registered at birth. Gender-affirming hormone treatment (GAHT) and gender-affirming surgery may alter reproductive function and/or anatomy, limiting future reproductive options to varying degrees, if individuals desire to either give birth and, or to become a biological parent. TGD people increasingly pursue help for their reproductive questions, including fertility and fertility preservation. Their specific needs certainly require more insight into the effects of GAHT on gonads, gametes and fertility. This talk aims to provide an overview of the current knowledge on the impact of GAHT on gonads, gametes, fertility, fertility preservation techniques, and outcomes after performing a literature search (in PubMed, Embase, and Web of Science) In TGD people using GAHT, histological changes have been reported in both people registered female at birth and people registered male at birth. Using testosterone GAHT, cortical and stromal changes were reported by various studies. In most studies, persistent activity in folliculogenesis can be concluded based on the descriptions of the follicle count, distribution, and oocyte retrieval yield. However, there may be a negative effect on fertilisation rate in the presence of testosterone. Reports on successful ovarian stimulation, fertilisation, pregnancies and live births have been published, describing cases with and without testosterone discontinuation. After using oestrogen GAHT, testes are reported to be more atrophic, including smaller seminiferous tubules with heavy hyalinisation and fibrosis. Spermatogenic levels varied widely from complete spermatogenesis to meiotic arrest with spermatids, to spermatogonial arrest, Sertoli cell-only or even tubular shadows. Oestrogen and anti-androgen treatment causes higher proportions of sperm abnormalities (low total sperm count, low sperm concentration, poor sperm motility) or azoospermia. However, after cessation, this may be restored. Although knowledge of the effect of GAHT is growing, specific areas remain to be uncovered. Therefore, additional research in this specific population is needed, preferably comparing outcomes before and after the start of GAHT and also including pre-pubertal and peri-pubertal persons. This may help to reveal the pure impact of GAHT on reproductive functioning. Research suggestions also include the reversibility of the GAHT effect, especially for those who start transition at a young age. Looking carefully at the presented data on GAHT effects on gonads and gametes, the correct advice is to assess and reassess reproductive wishes and preferences repeatedly. Furthermore, to also adjust to individual fertility preservation needs during gender-affirming treatment given the expanding knowledge and therapy opportunities. Finally, long-term health outcomes and quality of life of children born by the use of (preserved) gametes exposed to GAHT need to be prospectively followed up.
Zitieren
APA
Schneider, F., Roo, C. D., Stoop, D., & Mello, N. V. (2026). L26/O-303 Options for fertility preservation in persons assigned male at birth. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.301
Vancouver
Schneider F, Roo CD, Stoop D, Mello NV. L26/O-303 Options for fertility preservation in persons assigned male at birth. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.301
BibTeX
@article{Schneider2026,
author = {Schneider, F. and Roo, C. De and Stoop, D. and Mello, N. Van},
title = {L26/O-303 Options for fertility preservation in persons assigned male at birth},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.301}
}
EUVIMED